Ruxolitinib Clinical Trials

34 actively recruiting trials across 14 locations

▼ -3 trials since August 2026

Also known as: (3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile, 941678-49-5, INCB 018424, INCB-018424, INCB-18424 +6 more

Pipeline

Early 1: 1Phase 1: 11Phase 2: 14Phase 3: 1Phase 1/2: 6

Top Sponsors

M.D. Anderson Cancer Center4
Memorial Sloan Kettering Cancer Center3
University of Chicago2
St. Petersburg State Pavlov Medical University2
Mayo Clinic2

Indications

Cancer34
Polycythemia Vera4
T-cell Prolymphocytic Leukemia3
Peripheral T Cell Lymphoma3
Essential Thrombocythemia3

Other6 trials

BeFluBu vs FluBuRux Conditioning in Haploidentical HCT

Phase 2

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Phase 1/2

MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

Phase 3

MRD-positive AML Clinical Study

N/A

Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor

Phase 2

Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV

Phase 2

Chicago, Illinois4 trials

Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation

University of Chicago Medicine Comprehensive Cancer Center

Phase 1

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

University of Illinois Cancer Center

Phase 1/2

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

University of Chicago Medical Center

Phase 1

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Rush University

Phase 1/2

Houston, Texas4 trials

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

M D Anderson Cancer Center

Early 1

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

MD Anderson Cancer Center

Phase 2

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

The University of Texas M. D. Anderson Cancer Center

Phase 1/2

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

The University of Texas M. D. Anderson Cancer Center

Phase 1/2

Miami, Florida3 trials

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

University of Miami (Data Collection Only)

Phase 1

Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

Baptist Health Herbert Wertheim Cancer Institute

Phase 2

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

University of Miami

Phase 2

Seattle, Washington3 trials

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 1

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Scottsdale, Arizona2 trials

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Mayo Clinic in Arizona

Phase 1

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Mayo Clinic in Arizona

Phase 1

Duarte, California2 trials

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

City of Hope

Phase 1

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

City of Hope Medical Center

Phase 1

Boston, Massachusetts2 trials

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

Dana-Farber Cancer Institute

Phase 2

Ruxolitinib in Thrombocythemia and Polycythemia Vera

Massachusetts General Hospital

Phase 2

Columbus, Ohio2 trials

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1

Birmingham, Alabama1 trial

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

The University of Alabama at Birmingham

Phase 2

La Jolla, California1 trial

Retifanlimab and Ruxolitinib In Solid Malignancies

University of California, San Diego Moores Cancer Center

Phase 1/2

West Hollywood, California1 trial

A Trial of Selinexor, Ruxolitinib and Methylprednisolone

Berenson Cancer Center

Phase 1

Basking Ridge, New Jersey1 trial

A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

New York, New York1 trial

Amping up With PemJAK

Columbia University Irving Medical Center

Phase 2

Portland, Oregon1 trial

Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

OHSU Knight Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.